What is Wedbush's Forecast for TSE:FRX FY2026 Earnings?

Key Points

• Wedbush has lowered its FY2026 earnings estimate for Fennec Pharmaceuticals to $0.62 per share, down from a previous forecast of $0.76.
• Fennec Pharmaceuticals' stock dropped 7.4% following the revised earnings outlook and currently trades at C$12.30.
• Insider trading activity included the sale of 26,900 shares by Southpoint Capital Advisors, indicating a decrease in ownership among insiders.

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Wedbush lowered their FY2026 earnings estimates for shares of Fennec Pharmaceuticals in a research note issued on Monday, October 13th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.62 per share for the year, down from their prior forecast of $0.76. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share.

Fennec Pharmaceuticals Stock Down 7.4%

FRX opened at C$12.30 on Tuesday. The company has a fifty day moving average price of C$12.23 and a 200-day moving average price of C$10.78. The firm has a market capitalization of C$342.33 million, a P/E ratio of -27.33 and a beta of 2.48. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$13.83.

Insider Activity at Fennec Pharmaceuticals

In related news, insider Southpoint Capital Advisors Lp sold 26,900 shares of the company's stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of C$13.23, for a total value of C$355,887.00. Following the completion of the transaction, the insider directly owned 4,050,314 shares in the company, valued at approximately C$53,585,654.22. The trade was a 0.66% decrease in their ownership of the stock. In the last ninety days, insiders have sold 68,889 shares of company stock worth $900,406. 16.20% of the stock is owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.